G. Pond

发表

Measured and estimated GFR in healthy potential kidney donors.

T. Larson, A. Rule, H. Gussak, 2004, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Rectal-wall dose dependence on postplan timing after permanent-seed prostate brachytherapy.

G. Pond, D. Taussky, I. Yeung, 2006, International journal of radiation oncology, biology, physics.

Sequential evaluation of prostate edema after permanent seed prostate brachytherapy using CT-MRI fusion.

Ivan Yeung, Daniel Taussky, Gregory Pond, 2004, International journal of radiation oncology, biology, physics.

The position of the polycystic kidney disease 1 (PKD1) gene mutation correlates with the severity of renal disease.

Gregory R Pond, Klaus Zerres, G. Pond, 2002, Journal of the American Society of Nephrology : JASN.

Seamless Designs: Current Practice and Considerations for Early-Phase Drug Development in Oncology

G. Rosner, G. Pond, L. Seymour, 2018, Journal of the National Cancer Institute.

Impact of wait times on survival for women with uterine cancer.

G. Pond, L. Elit, E. O'Leary, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Medication Reconciliation at Hospital Discharge: Evaluating Discrepancies

Annemarie Cesta, J. Bajcar, Olavo A Fernandes, 2008, The Annals of pharmacotherapy.

Randomized phase II trials: inevitable or inadvisable?

D. Sargent, G. Pond, M. Moore, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Intraobserver and interobserver variability in GTV delineation on FDG-PET-CT images of head and neck cancers.

Brian O'Sullivan, Kristy Brock, Eugene Yu, 2007, International journal of radiation oncology, biology, physics.

Epigenetic silencing of miR-145-5p contributes to brain metastasis

Andrea Sacconi, Paola Muti, Yosef Yarden, 2015, Oncotarget.

Association of Metformin with Breast Cancer Incidence and Mortality in Patients with Type II Diabetes: A GRADE-Assessed Systematic Review and Meta-analysis

G. Pond, H. Schünemann, P. Muti, 2018, Cancer Epidemiology, Biomarkers & Prevention.

Trends in the application of dynamic allocation methods in multi-arm cancer clinical trials

Gregory R Pond, G. Pond, S. Welch, 2010, Clinical trials.

Phase 1 trial design: is 3 + 3 the best?

Gregory R Pond, G. Pond, L. Siu, 2014, Cancer control : journal of the Moffitt Cancer Center.

Effects of de-escalated bisphosphonate therapy on bone turnover biomarkers in breast cancer patients with bone metastases

G. Pond, M. Clemons, C. Addison, 2014, SpringerPlus.

Learning Health System for Breast Cancer: Pilot Project Experience.

G. Pond, A. Sathiyapalan, M. Levine, 2019, JCO clinical cancer informatics.

Changes in Soft-Tissue Sarcoma Treatment Patterns over Time: A Population-Based Study in a Country with Universal and Centralized Healthcare

G. Pond, M. Ghert, H. Seow, 2019, Sarcoma.

Clinical studies.

G. Pond, A. Oza, J. Dancey, 2000, Women alive.

Vasomotor symptoms in early breast cancer—a “real world” exploration of the patient experience

G. Pond, K. Emam, M. Clemons, 2022, Supportive Care in Cancer.

Quantitative evaluation of single-arm versus randomized phase II cancer clinical trials

G. Pond, Saqib Abbasi, 2011, Clinical trials.

Stopping rules employing response rates, time to progression, and early progressive disease for phase II oncology trials

G. Pond, J. Goffin, 2011, BMC medical research methodology.

Treatment of Hormone-Refractory Prostate Cancer with Docetaxel or Mitoxantrone: Relationships between Prostate-Specific Antigen, Pain, and Quality of Life Response and Survival in the TAX-327 Study

G. Pond, R. de Wit, M. Eisenberger, 2008, Clinical Cancer Research.

Potential value of Gleason score in predicting the benefit of cabazitaxel in metastatic castration-resistant prostate cancer.

G. Pond, G. Sonpavde, G. Di Lorenzo, 2013, Future oncology.

Evaluating survivorship care plans: results of a randomized, clinical trial of patients with breast cancer.

G. Pond, D. Coyle, A. Robidoux, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The wait time creep: changes in the surgical wait time for women with uterine cancer in Ontario, Canada, during 2000-2009.

G. Pond, L. Elit, E. O'Leary, 2013, Gynecologic oncology.

Evaluating the Feasibility of Performing Window of Opportunity Trials in Breast Cancer

G. Pond, M. Clemons, C. Addison, 2015, International journal of surgical oncology.

Factors influencing survival among patients with HER2-positive metastatic breast cancer treated with trastuzumab

M. Yaffe, G. Pond, J. Bartlett, 2018, Breast Cancer Research and Treatment.

Comparison of outcomes of phase II studies and subsequent randomized control studies using identical chemotherapeutic regimens.

G. Pond, L. Siu, E. Chen, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Taxane acute pain syndrome (TAPS) in patients receiving chemotherapy for breast or prostate cancer: a prospective multi-center study

G. Pond, S. Damaraju, B. Hutton, 2018, Supportive Care in Cancer.

Phase I/II trial of erlotinib and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a Princess Margaret Hospital phase II consortium and National Cancer Institute of Canada Clinical Trials Group Study.

G. Pond, E. Eisenhauer, J. Dancey, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cost effectiveness of a survivorship care plan for breast cancer survivors.

G. Pond, D. Coyle, K. Coyle, 2014, Journal of oncology practice.

Adjuvant bisphosphonate use in patients with early stage breast cancer: Patient perspectives on treatment acceptability and potential de-escalation

G. Pond, B. Hutton, M. Clemons, 2021, Journal of bone oncology.

"PSA-itis": knowledge of serum prostate specific antigen and other causes of anxiety in men with metaststic prostate cancer.

I. Tannock, G. Pond, A. Lofters, 2002, The Journal of urology.

Quality of preoperative pelvic computed tomography (CT) and magnetic resonance imaging (MRI) for rectal cancer in a region in Ontario: A retrospective population‐based study

G. Pond, S. Tsai, K. Zbuk, 2018, Journal of surgical oncology.

MEDiastinal Irradiation and CArdio-Toxic Effects (MEDICATE): Exploring the Relationship between Cardiac Irradiation and High Sensitivity Troponins.

G. Pond, S. Sagar, D. Leong, 2019, Clinical oncology (Royal College of Radiologists (Great Britain)).

Prognostic Impact of C-Reactive Protein in Metastatic Prostate Cancer: A Systematic Review and Meta-Analysis

G. Pond, G. Naik, G. Sonpavde, 2014, Oncology Research and Treatment.

Ability of C‐reactive protein to complement multiple prognostic classifiers in men with metastatic castration resistant prostate cancer receiving docetaxel‐based chemotherapy

G. Pond, G. Sonpavde, M. Galsky, 2012, BJU international.

Comparison of Multiparametric Magnetic Resonance Imaging-Targeted Biopsy With Systematic Transrectal Ultrasonography Biopsy for Biopsy-Naive Men at Risk for Prostate Cancer: A Phase 3 Randomized Clinical Trial.

C. Earle, G. Pond, M. Haider, 2021, JAMA oncology.

Optimal pathological response after neoadjuvant chemotherapy for muscle‐invasive bladder cancer: results from a global, multicentre collaboration

G. Pond, G. Sonpavde, J. Tward, 2021, BJU international.

A protocol for the VISION study: An indiVidual patient data meta-analysis of randomised trials comparing MRI-targeted biopsy to standard transrectal ultraSound guided bIopsy in the detection of prOstate cancer

G. Pond, B. Levis, M. Haider, 2022, PloS one.

Extent of Surgical Resection in Inflammatory Bowel Disease Associated Colorectal Cancer: a Population-Based Study

G. Pond, H. Seow, M. Šimunović, 2021, Journal of Gastrointestinal Surgery.

Endometrial cancer presentation is associated with social determinants of health in a public healthcare system: A population-based cohort study.

G. Pond, L. Elit, H. Seow, 2020, Gynecologic oncology.

A randomized, double-blind, window of opportunity trial evaluating the effects of chloroquine in breast cancer patients

G. Pond, Hoyun Lee, M. Clemons, 2019, Breast Cancer Research and Treatment.

Adherence to surveillance guidelines after curative resection for stage II/III colorectal cancer.

G. Pond, J. Brierley, L. Siu, 2008, Clinical colorectal cancer.

Sucralfate mouthwash for prevention and treatment of 5-fluorouracil-induced mucositis: a randomized, placebo-controlled trial

G. Pond, A. Oza, D. Hedley, 2002, Supportive Care in Cancer.

Fatigue in people with localized colorectal cancer who do and do not receive chemotherapy: a longitudinal prospective study.

I. Tannock, G. Pond, S. Clarke, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Reply from Authors re: Tracy L. Rose, Matthew I. Milowsky. A Small Step Toward Improving Salvage Treatment for Metastatic Bladder Cancer--At What Cost? Eur Urol 2016;69:642-44: Combination Chemotherapy as a Viable Salvage Therapy Strategy for Advanced Urothelial Carcinoma.

G. Pond, G. Sonpavde, J. Bellmunt, 2016, European urology.

A Multicenter Phase II Study of “Adjuvant” Irinotecan Following Resection of Colorectal Hepatic Metastases

G. Pond, H. Mackay, S. Gallinger, 2005, American journal of clinical oncology.

Expression of EGFR, HER-2/neu and KIT in germ cell tumours

G. Pond, L. Paz-Ares, C. Ballestín, 2010, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

A Phase II Multi-institutional Clinical Trial Assessing Fractionated Simultaneous In-Field Boost Radiotherapy for Brain Oligometastases

G. Pond, B. Fisher, B. Yaremko, 2019, Cureus.

Tolerability and efficacy of docetaxel in older men with metastatic castrate-resistant prostate cancer (mCRPC) in the TAX 327 trial.

I. Tannock, G. Pond, R. de Wit, 2011, Journal of geriatric oncology.

The impact of preoperative imaging on wait times, surgical approach and overall survival in endometrioid endometrial cancers.

G. Pond, L. Elit, E. O'Leary, 2022, Gynecologic oncology.

The use of imaging in endometrial cancer prior to potential surgery: Are guidelines being followed?

G. Pond, L. Elit, E. O'Leary, 2021, Gynecologic oncology.

Disparities in treatment patterns and outcomes among younger and older adults with newly diagnosed multiple myeloma: A population-based study.

G. Pond, H. Seow, T. Wildes, 2020, Journal of geriatric oncology.

Symptom burden in transplant-ineligible patients with newly diagnosed multiple myeloma: a population-based cohort study

G. Pond, H. Seow, T. Wildes, 2020, Haematologica.

Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial.

G. Pond, A. Oza, D. Hedley, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

C-statistic: A brief explanation of its construction, interpretation and limitations.

G. Pond, G. Sonpavde, S. Caetano, 2017, European journal of cancer.

Effect of Single‐agent Daily Prednisone on Outcomes and Toxicities in Metastatic Castration‐resistant Prostate Cancer: Pooled Analysis of Prospective Studies

G. Pond, G. Sonpavde, P. Ghatalia, 2017, Clinical genitourinary cancer.

Efficacy and Safety of Gemcitabine Plus Either Taxane or Carboplatin in the First‐Line Setting of Metastatic Urothelial Carcinoma: A Systematic Review and Meta‐Analysis

G. Pond, G. Sonpavde, M. Galsky, 2017, Clinical genitourinary cancer.

The Impact of Adding Taxanes to Gemcitabine and Platinum Chemotherapy for the First-Line Therapy of Advanced or Metastatic Urothelial Cancer: A Systematic Review and Meta-analysis.

G. Pond, G. Naik, G. Sonpavde, 2016, European urology.

Randomized window of opportunity trial evaluating high-dose vitamin D in breast cancer patients

G. Pond, M. Clemons, A. Arnaout, 2019, Breast Cancer Research and Treatment.

Patterns of Relapse in Small Cell Lung Cancer: Competing Risks of Thoracic versus CNS Relapse

G. Pond, P. Ellis, A. Swaminath, 2021, Current oncology.

Prognostic and Predictive Factors in Patients with Advanced Penile Cancer Receiving Salvage (2nd or Later Line) Systemic Treatment: A Retrospective, Multi-Center Study

G. Pond, G. Naik, G. Sonpavde, 2016, Frontiers in pharmacology.

Impact of the number of prior lines of therapy and prior perioperative chemotherapy in patients receiving salvage therapy for advanced urothelial carcinoma: implications for trial design.

G. Pond, P. Albers, T. Choueiri, 2015, Clinical genitourinary cancer.

Correlation of baseline biomarkers with clinical outcomes and response to fulvestrant with vandetanib or placebo in patients with bone predominant metastatic breast cancer: An OCOG ZAMBONEY sub-study

G. Pond, S. Chia, M. Clemons, 2015, Journal of bone oncology.

Radiographic progression by Prostate Cancer Working Group (PCWG)‐2 criteria as an intermediate endpoint for drug development in metastatic castration‐resistant prostate cancer

G. Pond, M. Michaelson, G. Sonpavde, 2014, BJU international.

Az erlotinib és cisplatin I/II. fázisú vizsgálata kiújuló vagy áttétes fej-nyaki laphámrákokban: a Princess Margaret Hospital Phase II Consortium és a National Institute of Canada Clinical Trials Group Study

G. Pond, E. Eisenhauer, J. Dancey, 2013 .

Impact of response to prior chemotherapy in patients with advanced urothelial carcinoma receiving second-line therapy: implications for trial design.

G. Pond, P. Albers, T. Choueiri, 2013, Clinical genitourinary cancer.

Association between radiographic response and overall survival in men with metastatic castration-resistant prostate cancer receiving chemotherapy.

I. Tannock, G. Pond, G. Sonpavde, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Chemotherapy with gemcitabine‐containing regimens for locally recurrent or metastatic nasopharyngeal carcinoma

I. Tannock, G. Pond, L. Siu, 2002, Cancer.

Favorable overall survival with fully myeloablative allogeneic stem cell transplantation for follicular lymphoma.

G. Pond, R. Tsang, J. Lipton, 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

A population-based analysis of spirometry use and the prevalence of chronic obstructive pulmonary disease in lung cancer

G. Pond, J. Goffin, Grace H. Tang, 2021, BMC Cancer.

Thyroid hormone receptor beta-1 expression in early breast cancer: a validation study

G. Pond, S. Narod, K. Pritchard, 2018, Breast Cancer Research and Treatment.

Influence of censoring on conclusions of trials for women with metastatic breast cancer.

I. Tannock, G. Pond, F. Vera-Badillo, 2015, European journal of cancer.

Fluorescence in situ hybridization gene amplification analysis of EGFR and HER2 in patients with malignant salivary gland tumors treated with lapatinib

G. Pond, J. Dancey, M. Tsao, 2009, Head & neck.

Understanding the attitudes of the elderly towards enrolment into cancer clinical trials

Kelvin K. W. Chan, G. Pond, S. Straus, 2006, BMC Cancer.

Phase II multicenter open‐label study of carboplatin and pegylated liposomal doxorubicin in uterine and cervical malignancies

G. Pond, A. Oza, K. Swenerton, 2005, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

Genetic Counselling Referral Rates and Uptake of BRCA1 and BRCA2 Testing among Women Diagnosed with Serous Ovarian Cancer in a Tertiary Care Cancer Centre

G. Pond, L. Elit, K. Bell, 2013 .

Association of the Charlson comorbidity index and hypertension with survival in men with metastatic castration-resistant prostate cancer.

G. Pond, G. Sonpavde, M. Galsky, 2014, Urologic oncology.

Are O lder C ancer P atients B eing R eferred t o O ncologists? A M ail Q uestionnaire o f O ntario P rimary C are P ractitioners to E valuate T heir R eferral P atterns

G. Pond, S. Straus, L. Siu, 2003 .

Are older cancer patients being referred to oncologists? A mail questionnaire of Ontario primary care practitioners to evaluate their referral patterns.

G. Pond, S. Straus, L. Siu, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Is Access to Care Associated With Stage at Presentation and Survival for Melanoma Patients?

G. Pond, H. Seow, E. McWhirter, 2019, Journal of cutaneous medicine and surgery.

Barriers in phase I cancer clinical trials referrals and enrollment: five-year experience at the Princess Margaret Hospital

G. Pond, A. Oza, L. Siu, 2006, BMC Cancer.

Dynamic Angiogenic Switch as Predictor of Response to Chemotherapy-Bevacizumab in Patients With Metastatic Colorectal Cancer

G. Pond, M. Hidalgo, S. Perea, 2019, American journal of clinical oncology.

Making sense of prostate specific antigen: improving its predictive value in patients undergoing prostate biopsy.

G. Pond, J. Trachtenberg, L. Klotz, 2006, The Journal of urology.

Real-world practice patterns and attitudes towards de-escalation of bone-modifying agents in patients with bone metastases from breast and prostate cancer: A physician survey

G. Pond, B. Hutton, M. Clemons, 2020, Journal of bone oncology.

Perceptions around bone-modifying agent use in patients with bone metastases from breast and castration resistant prostate cancer: a patient survey

G. Pond, B. Hutton, M. Clemons, 2021, Supportive Care in Cancer.

Active Surveillance Magnetic Resonance Imaging Study (ASIST): Results of a Randomized Multicenter Prospective Trial.

G. Pond, M. Haider, J. Chin, 2019, European urology.

Conditional immune toxicity rate in patients with metastatic renal and urothelial cancer treated with immune checkpoint inhibitors

G. Pond, T. Choueiri, G. Sonpavde, 2020, Journal for ImmunoTherapy of Cancer.

Randomized Study of Systematic Biopsy Versus Magnetic Resonance Imaging and Targeted and Systematic Biopsy in Men on Active Surveillance (ASIST): 2-year Postbiopsy Follow-up.

G. Pond, M. Haider, J. Chin, 2019, European urology.

Statin Use and Survival in Patients with Metastatic Castration-resistant Prostate Cancer Treated with Abiraterone Acetate.

G. Pond, G. Sonpavde, B. Daniele, 2017, European urology focus.

The prognostic importance of metastatic site in men with metastatic castration-resistant prostate cancer.

I. Tannock, G. Pond, G. Sonpavde, 2014, European urology.

Efficacy of docetaxel-based chemotherapy following ketoconazole in metastatic castration-resistant prostate cancer: implications for prior therapy in clinical trials.

G. Pond, G. Sonpavde, M. Galsky, 2013, Urologic oncology.

Translating clinical trials to clinical practice: outcomes of men with metastatic castration resistant prostate cancer treated with docetaxel and prednisone in and out of clinical trials.

I. Tannock, G. Pond, M. Moore, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Using machine learning to predict individual patient toxicities from cancer treatments

G. Pond, K. Emam, M. Clemons, 2022, Supportive Care in Cancer.

A comparison of patient adherence and preference of packaging method for oral anticancer agents using conventional pill bottles versus daily pill boxes.

Victor C. M. Leung, G. Pond, L. Siu, 2007, European journal of cancer care.

Neutropenia as a potential pharmacodynamic marker for docetaxel-based chemotherapy in men with metastatic castration-resistant prostate cancer.

G. Pond, G. Sonpavde, M. Galsky, 2012, Clinical genitourinary cancer.

Robot-assisted Versus Open Radical Cystectomy in Patients Receiving Perioperative Chemotherapy for Muscle-invasive Bladder Cancer: The Oncologist's Perspective from a Multicentre Study.

G. Pond, T. Powles, N. Agarwal, 2017, European urology focus.

Data collection in cancer clinical trials: Too much of a good thing?

G. Pond, J. Julian, E. O'Leary, 2013, Clinical trials.

Lack of cognitive impairment in long-term survivors of colorectal cancer

I. Tannock, L. Waite, G. Pond, 2022, Supportive Care in Cancer.

The Contribution of Multiparametric Pelvic and Whole-Body MRI to Interpretation of 18F-Fluoromethylcholine or 68Ga-HBED-CC PSMA-11 PET/CT in Patients with Biochemical Failure After Radical Prostatectomy

G. Pond, A. Scott, S. Punwani, 2019, The Journal of Nuclear Medicine.

Incidence and predictors of prosthetic joint infection following primary total knee arthroplasty: A 15-year population-based cohort study.

M. Bhandari, G. Pond, A. Adili, 2021, The Journal of arthroplasty.

Circulating tumor DNA alterations in patients with metastatic castration‐resistant prostate cancer

G. Pond, G. Naik, N. Agarwal, 2019, Cancer.

Small-molecule XIAP inhibitors derepress downstream effector caspases and induce apoptosis of acute myeloid leukemia cells.

G. Pond, M. Minden, John Calvin Reed, 2005, Blood.

Serum alkaline phosphatase changes predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy.

I. Tannock, G. Pond, G. Sonpavde, 2012, Urologic oncology.

High-sensitivity cardiac troponin I for predicting death in a female emergency department population.

G. Pond, P. Kavsak, A. Worster, 2014, Clinical chemistry.

Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: a multicenter phase II trial.

G. Pond, K. Gelmon, S. Chia, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Heterogeneity among lists of cautioned or prohibited drugs in protocols of early-phase oncology trials.

G. Pond, L. Siu, E. Chen, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase 2 trial exploring the clinical and correlative effects of combining doxycycline with bone-targeted therapy in patients with metastatic breast cancer

G. Pond, M. Clemons, C. Addison, 2016, Journal of bone oncology.

Response to ‘Adverse cardiac outcomes in patients with chronic myeloid leukaemia treated with tyrosine kinase inhibitors’

G. Pond, H. Seow, C. Hillis, 2021, Heart.

Adjuvant bisphosphonate use in patients with early stage breast cancer: a physician survey

G. Pond, B. Hutton, M. Clemons, 2021, Breast Cancer Research and Treatment.

Prognostic stratification of post-docetaxel metastatic castration resistant prostate cancer (mCRPC) from a phase III randomized trial.

G. Pond, M. Michaelson, G. Sonpavde, 2012 .

Cisplatin-based first-line therapy for advanced urothelial carcinoma after previous perioperative cisplatin-based therapy.

G. Pond, N. Agarwal, G. Sonpavde, 2015, Clinical genitourinary cancer.

Phase II Weekly Vinblastine for Chemotherapy-Naïve Children With Progressive Low-Grade Glioma: A Canadian Pediatric Brain Tumor Consortium Study.

D. Johnston, G. Pond, D. Eisenstat, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Artichoke phytocomplex modulates serum microRNAs in patients exposed to asbestos: a first step of a phase II clinical trial

G. Pond, P. Muti, G. Blandino, 2022, Journal of experimental & clinical cancer research : CR.

Assessment of function and quality of life in a phase II multi-institutional clinical trial of fractionated simultaneous in-field boost radiotherapy for patients with 1–3 metastases

G. Pond, B. Fisher, L. Stitt, 2016, Journal of Neuro-Oncology.

Impact of single-agent daily prednisone on outcomes in men with metastatic castration-resistant prostate cancer

G. Pond, G. Sonpavde, J. Bono, 2016, Prostate Cancer and Prostatic Diseases.

A Prospective Study of 18F-DCFPyL PSMA PET/CT Restaging in Recurrent Prostate Cancer following Primary External Beam Radiotherapy or Brachytherapy.

Hans T. Chung, G. Pond, M. Lock, 2019, International journal of radiation oncology, biology, physics.

Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa.

I. Tannock, G. Pond, R. de Wit, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

The impact of synchronous malignancies on survival in patients with early stage curable non-small-cell lung cancer.

G. Pond, D. Langer, G. Darling, 2020, Cancer treatment and research communications.

550 POSTER Dual inhibition of the MAPK pathway by combination targeted therapy: a phase I trial of sorafenib (SOR) and erlotinib (ERL) in advanced solid tumors

G. Pond, J. Dancey, L. Siu, 2006 .

A phase I–II study of oblimersen sodium (G3139, Genasense) in combination with doxorubicin in advanced hepatocellular carcinoma (NCI # 5798)

G. Pond, S. Gill, J. Knox, 2008, Investigational New Drugs.

New 6-factor prognostic model for patients (pts) with advanced urothelial carcinoma (UC) receiving post-platinum atezolizumab.

G. Pond, T. Powles, T. Choueiri, 2018 .

Glasgow prognostic score as a prognostic factor in metastatic castration-resistant prostate cancer treated with docetaxel-based chemotherapy.

G. Pond, G. Sonpavde, M. Galsky, 2013, Clinical genitourinary cancer.

Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study.

S. Gabriel, G. Pond, W. O'Fallon, 2002, Arthritis and rheumatism.

Disparities in the survival of endometrial cancer patients in a public healthcare system: A population-based cohort study.

G. Pond, L. Elit, H. Seow, 2020, Gynecologic oncology.

Effect of geographic distance from a cancer centre on choice of systemic therapy in metastatic colorectal cancer.

G. Pond, M. Seal, T. Wilkieson, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer

G. Pond, A. Oza, J. Dancey, 2006, British Journal of Cancer.

Expanded phase II trial of gemcitabine and capecitabine for advanced biliary cancer

G. Pond, R. Riechelmann, J. Knox, 2007, Cancer.

Factors associated with acute care use among nursing home residents dying of cancer: a population-based study.

G. Pond, D. Bainbridge, H. Seow, 2015, International journal of palliative nursing.

A randomized double-blind placebo-controlled cross-over trial of the impact on quality of life of continuing dexamethasone beyond 24 h following adjuvant chemotherapy for breast cancer

I. Tannock, G. Pond, M. Clemons, 2012, Breast Cancer Research and Treatment.

Cisplatin- Versus Non-Cisplatin-based First-Line Chemotherapy for Advanced Urothelial Carcinoma Previously Treated With Perioperative Cisplatin.

G. Pond, P. Albers, N. Agarwal, 2016, Clinical genitourinary cancer.

Patient eligibility and trial design for the salvage therapy of advanced urothelial carcinoma.

G. Pond, P. Albers, T. Choueiri, 2014, Clinical genitourinary cancer.

Phase I trial of gemcitabine, doxorubicin and cisplatin (GAP) in patients with advanced solid tumors

G. Pond, A. Oza, L. Siu, 2006, Anti-cancer drugs.

A single agent, phase I pharmacodynamic study of nimotuzumab (TheraCIM-h-R3) in patients with advanced refractory solid tumors

G. Pond, A. Oza, D. Hedley, 2007 .

A phase II study of BAY 43–9006 in patients with recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC) and nasopharyngeal cancer (NPC)

G. Pond, L. Siu, O. Petrenciuc, 2005 .

Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus.

G. Pond, A. Oza, L. Seymour, 2006, European journal of cancer.

Gemcitabine concurrent with continuous infusional 5-fluorouracil in advanced biliary cancers: a review of the Princess Margaret Hospital experience.

G. Pond, A. Oza, D. Hedley, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

Treatment delay in endometrial cancer. Reply to J. Menczer.

G. Pond, L. Elit, H. Seow, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Natural history and chemotherapy effectiveness for advanced adenocarcinoma of the small bowel: a retrospective review of 113 cases.

G. Pond, A. Oza, M. Moore, 2006, American journal of clinical oncology.

A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas

G. Pond, A. Oza, D. Birle, 2006, British Journal of Cancer.

Incomplete Cross-Resistance Between Taxanes for Advanced Urothelial Carcinoma: Implications for Clinical Practice and Trial Design.

G. Pond, T. Choueiri, G. Sonpavde, 2015, Clinical genitourinary cancer.

Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trials.

G. Pond, P. Albers, T. Choueiri, 2013, European urology.

Initial versus recent outcomes with a non–risk adapted surveillance policy in stage I non-seminomatous germ cell tumors (NSGCT)

G. Pond, P. Warde, M. Moore, 2007 .

Outcomes in patients with advanced urothelial carcinoma after discontinuation of programmed death (PD)‐1 or PD ligand 1 inhibitor therapy

G. Pond, T. Powles, G. Sonpavde, 2017, BJU international.

Impact of Prior Platinum-Based Therapy on Patients Receiving Salvage Systemic Treatment for Advanced Urothelial Carcinoma.

H. Kume, G. Pond, P. Albers, 2016, Clinical genitourinary cancer.

Impact of number of lines of prior chemotherapy in patients (pts) with advanced urothelial carcinoma (UC) receiving salvage therapy.

G. Pond, P. Albers, T. Choueiri, 2014 .

Impact of prior platinum agent and site of primary in patients with advanced urothelial carcinoma (UC) receiving salvage therapy.

G. Pond, P. Albers, T. Choueiri, 2014 .

Nomogram to predict the benefit from salvage systemic therapy for advanced urothelial carcinoma

G. Pond, G. Sonpavde, J. Bellmunt, 2015, BJU international.

Intraoperative Sonographically Assisted Radioactive Iodine 125 Plaque Brachytherapy for Choroidal Melanoma

G. Pond, G. Shenouda, T. AlMahmoud, 2013, Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine.

Discordance between IHC and ERBB2 mRNA to Determine HER2 Low Status for Breast Cancer.

G. Pond, D. Rea, C. Seynaeve, 2022, The Journal of molecular diagnostics : JMD.

Outcomes of Adjuvant Therapy for Stage IA Serous Endometrial Cancer

G. Pond, S. Voruganti, L. Elit, 2018, Cureus.

Clinical Outcomes of Perioperative Chemotherapy in Patients With Locally Advanced Penile Squamous‐Cell Carcinoma: Results of a Multicenter Analysis

G. Pond, V. Khoo, G. Sonpavde, 2017, Clinical genitourinary cancer.

Cognitive Function in Patients With Colorectal Cancer Who Do and Do Not Receive Chemotherapy: A Prospective, Longitudinal, Controlled Study.

I. Tannock, G. Pond, P. Beale, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Nomogram to Assess the Survival Benefit of New Salvage Agents for Metastatic Urothelial Carcinoma in the Era of Immunotherapy

G. Pond, T. Choueiri, G. Sonpavde, 2018, Clinical genitourinary cancer.

A Randomized Trial Comparing 3- versus 4-Monthly Cardiac Monitoring in Patients Receiving Trastuzumab-Based Chemotherapy for Early Breast Cancer

G. Pond, B. Hutton, M. Clemons, 2021, Current oncology.

A randomised trial of 4- versus 12-weekly administration of bone-targeted agents in patients with bone metastases from breast or castration-resistant prostate cancer

G. Pond, B. Hutton, M. Clemons, 2020, European Journal of Cancer.

Phase I trial of UCN-01 in combination with topotecan in patients with advanced solid cancers: a Princess Margaret Hospital Phase II Consortium study.

G. Pond, A. Oza, J. Dancey, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

A mechanistic cohort study evaluating cognitive impairment in women treated for breast cancer

Myrle M. Stouten-Kemperman, I. Tannock, A. Crawley, 2019, Brain Imaging and Behavior.

Randomized phase II placebo-controlled trial of fulvestrant plus vandetanib in postmenopausal women with bone only or bone predominant, hormone receptor-positive metastatic breast cancer (MBC): OCOG Zamboney study—NCT00811369.

G. Pond, A. Robidoux, S. Chia, 2013 .

Outcome of patients who develop acute leukemia or myelodysplasia as a second malignancy after solid tumors treated surgically or with strategies that include chemotherapy and/or radiation

G. Pond, M. Minden, N. Mitsakakis, 2008, Cancer.

Nomogram prediction for prostate cancer and aggressive prostate cancer at time of biopsy: utilizing all risk factors and tumor markers for prostate cancer.

G. Pond, J. Trachtenberg, L. Klotz, 2006, The Canadian journal of urology.

Feasibility outcomes of a randomised, multicentre, pilot trial comparing standard 6-monthly dosing of adjuvant zoledronate with a single one-time dose in patients with early stage breast cancer

G. Pond, B. Hutton, M. Clemons, 2020, Journal of bone oncology.

Cost-Effectiveness Analysis of 12-Versus 4-Weekly Administration of Bone-Targeted Agents in Patients with Bone Metastases from Breast and Castration-Resistant Prostate Cancer

G. Pond, M. Clemons, K. Thavorn, 2021, Current oncology.

Perceived cognitive impairment in people with colorectal cancer who do and do not receive chemotherapy

I. Tannock, G. Pond, S. Rourke, 2018, Journal of Cancer Survivorship.

A multi-centre, randomised trial comparing schedules of G-CSF (filgrastim) administration for primary prophylaxis of chemotherapy-induced febrile neutropenia in early stage breast cancer.

G. Pond, M. Clemons, D. Fergusson, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Cabozantinib for Progressive Metastatic Castration-resistant Prostate Cancer Following Docetaxel: Combined Analysis of Two Phase 3 Trials.

G. Pond, E. Basch, G. Sonpavde, 2020, European urology oncology.

Hypofractionated Stereotactic Radiotherapy for the Treatment of Benign Intracranial Meningiomas: Long-Term Safety and Efficacy

G. Pond, A. Whitton, J. Greenspoon, 2021, Current oncology.

Clinical Outcomes of Platinum-ineligible Patients with Advanced Urothelial Carcinoma Treated With First-line PD1/L1 Inhibitors.

G. Pond, G. Sonpavde, P. Barata, 2021, Clinical genitourinary cancer.

The LISA randomized trial of a weight loss intervention in postmenopausal breast cancer

G. Pond, J. Gralow, A. Robidoux, 2020, npj Breast Cancer.

A randomised controlled trial evaluating two cognitive rehabilitation approaches for cancer survivors with perceived cognitive impairment

G. Pond, H. Dhillon, M. Bell, 2022, Journal of cancer survivorship : research and practice.

Using machine learning to predict individual patient toxicities from cancer treatments

G. Pond, K. Emam, M. Clemons, 2022, Supportive Care in Cancer.

Treatment and Clinical Outcomes of Patients with Teratoma with Somatic-Type Malignant Transformation: An International Collaboration.

G. Pond, G. Sonpavde, L. Einhorn, 2015, The Journal of urology.

Prospective, Multisite, International Comparison of 18F-Fluoromethylcholine PET/CT, Multiparametric MRI, and 68Ga-HBED-CC PSMA-11 PET/CT in Men with High-Risk Features and Biochemical Failure After Radical Prostatectomy: Clinical Performance and Patient Outcomes

G. Pond, A. Scott, S. Punwani, 2018, The Journal of Nuclear Medicine.

Correlation between changes in 2- or 3-year disease-free survival (DFS) and 5-year overall survival (OS) in adjuvant breast cancer trials from 1966–2006

G. Pond, L. Siu, P. Tang, 2007 .

Long-term urinary sequelae following 125iodine prostate brachytherapy.

G. Pond, J. Crook, N. Fleshner, 2008, The Journal of urology.

Assessment of the downstream portion of the mitochondrial pathway of caspase activation in patients with acute myeloid leukemia

G. Pond, M. Minden, R. Wells, 2005, Apoptosis.

Safety and antitumor activity of selinexor (KPT-330), a first-in-class, oral XPO1 selective inhibitor of nuclear export: A phase I study expanded with colon cancer cohort.

G. Pond, A. Oza, A. Shields, 2014 .

Anti Tumor Activity Of Selinexor (KPT-330), A First-In-Class Oral Selective Inhibitor Of Nuclear Export (SINE) XPO1/CRM1 Antagonist In Patients (pts) With Relapsed / Refractory Multiple Myeloma (MM) Or Waldenstrom’s Macroglobulinemia (WM)

J. Byrd, G. Pond, A. Oza, 2013 .

Preliminary Evidence Of Anti Tumor Activity Of Selinexor (KPT-330) In a Phase I Trial Ofa First-In-Class Oral Selective Inhibitor Of Nuclear Export (SINE) In Patients (pts) With Relapsed / Refractory Non Hodgkin’s Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

J. Byrd, G. Pond, A. Oza, 2013 .

Phase I Trial of Selinexor (KPT-330), A First-In-Class Oral Selective Inhibitor Of Nuclear Export (SINE) In Patients (pts) With Advanced Acute Myelogenous Leukemia (AML)

J. Byrd, G. Pond, A. Oza, 2013 .

First-in-class, first-in-human phase I trial of KPT-330, a selective inhibitor of nuclear export (SINE) in patients (pts) with advanced solid tumors.

G. Pond, A. Oza, A. Razak, 2013 .

Randomized trial of a lifestyle intervention for women with early-stage breast cancer (BC) receiving adjuvant hormone therapy: Initial results.

G. Pond, P. Goodwin, K. Pritchard, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

PSA declines and survival in patients with metastatic castration-resistant prostate cancer treated with enzalutamide

G. Pond, G. Sonpavde, B. Daniele, 2017, Medicine.

Randomized trial of a telephone-based weight loss intervention in postmenopausal women with breast cancer receiving letrozole: the LISA trial.

G. Pond, J. Gralow, A. Robidoux, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I/II study of GTI-2040 plus docetaxel as 2nd-line treatment in non-small cell lung cancer (NSCLC) and other solid tumors

G. Pond, F. Shepherd, P. Ellis, 2005 .

P4-12-05: Impact of the Lifestyle Intervention Study in Adjuvant Treatment of Early Breast Cancer (LISA) Weight Loss Intervention upon Physical Activity.

G. Pond, P. Goodwin, K. Pritchard, 2011 .

Outcomes of trimodality bladder-sparing therapy for muscle-invasive bladder cancer.

G. Pond, A. Neville, S. Hotte, 2019, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

Cytokine levels in patients (pts) with colorectal cancer and breast cancer and their relationship to fatigue and cognitive function

I. Tannock, G. Pond, S. Clarke, 2007 .

A phase II study of the antisense oligonucleotide GTI-2040 plus docetaxel and prednisone as first line treatment in hormone refractory prostate cancer (HRPC).

G. Pond, M. Moore, S. Hotte, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of sorafenib (BAY 43-9006) in combination with gemcitabine in recurrent epithelial ovarian cancer: A PMH phase II consortium trial.

G. Pond, A. Oza, H. Hirte, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Concurrent chemoradiotherapy for men with locally advanced penile squamous cell carcinoma.

G. Pond, G. Sonpavde, M. Milowsky, 2014, Clinical genitourinary cancer.

Phase II study of the angiogenesis inhibitor AZD2171 in first line, progressive, unresectable, advanced metastatic renal cell carcinoma (RCC): A trial of the PMH Phase II Consortium

G. Pond, M. Haider, M. Moore, 2007 .

Comparative survival in patients with brain metastases from non-small-cell lung cancer treated before and after implementation of radiosurgery.

G. Pond, P. Ellis, A. Swaminath, 2017, Current oncology.

Active surveillance magnetic resonance imaging study (ASIST): Results of a prospective, multicentre, randomized trial

G. Pond, M. Haider, J. Chin, 2018 .

Impact and perceptions of mandatory tumor biopsies for correlative studies in clinical trials of novel anticancer agents.

G. Pond, A. Oza, L. Siu, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Biased Evaluation in Cancer Drug Trials-How Use of Progression-Free Survival as the Primary End Point Can Mislead.

I. Tannock, G. Pond, C. Booth, 2022, JAMA oncology.

Expanded phase I study of vorinostat (VOR) in combination with capecitabine (CAP) in patients (pts) with advanced solid tumors

G. Pond, A. Oza, L. Siu, 2007 .

Predictive and pharmacodynamic biomarker studies in tumor and skin tissue samples of patients with recurrent or metastatic squamous cell carcinoma of the head and neck treated with erlotinib.

G. Pond, J. Dancey, M. Tsao, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Association of Neurocognitive Deficits With Radiotherapy or Chemoradiotherapy for Patients With Head and Neck Cancer

Kelvin K. W. Chan, G. Pond, J. Waldron, 2017, JAMA otolaryngology-- head & neck surgery.

Metformin-A Thought-Provoking Addition to Anticancer Therapies-Reply.

G. Pond, T. Tsakiridis, J. Wright, 2021, JAMA oncology.

Comparison of outcomes between abdominal, minimally invasive and combined vaginal-laparoscopic hysterectomy in patients with stage IAI/IA2 cervical cancer: 4C (Canadian Cervical Cancer Collaborative) study.

G. Pond, J. Kwon, L. Elit, 2021, Gynecologic oncology.

Role of fractionated external beam radiotherapy in hemangioblastoma of the central nervous system.

G. Pond, C. Ménard, A. Nichol, 2007, International journal of radiation oncology, biology, physics.

Does the number of 6-monthly adjuvant zoledronate infusions received affect treatment efficacy for early breast cancer? A sub-study of ABCSG-12.

G. Pond, M. Gnant, M. Clemons, 2022, European journal of cancer.

Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands.

D. Hayes, G. Pond, J. Dancey, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II Study of Lapatinib in Recurrent or Metastatic Epidermal Growth Factor Receptor and / or erbB 2 Expressing Adenoid Cystic Carcinoma and Non – Adenoid Cystic Carcinoma Malignant Tumors of the Salivary Glands

D. Hayes, G. Pond, J. Dancey, 2007 .

Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma.

G. Pond, L. Siu, J. Elting, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Predictors of infection in rheumatoid arthritis.

S. Gabriel, G. Pond, W. O'Fallon, 2002, Arthritis and rheumatism.

Early stopping rules in oncology: considerations for clinicians.

G. Pond, K. Anderson, J. Goffin, 2011, European journal of cancer.

A Phase II study of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) and gemcitabine in advanced pancreatic carcinoma. A trial of the Princess Margaret Hospital Phase II consortium

G. Pond, J. Low, M. Mackenzie, 2007, Investigational New Drugs.

Dermopathy of Graves' disease (pretibial myxedema): long-term outcome.

G. Pond, V. Fatourechi, K. Schwartz, 2002, The Journal of clinical endocrinology and metabolism.

Radiation therapy for Bowen's disease of the skin.

G. Pond, R. Tsang, W. Wells, 2004, International journal of radiation oncology, biology, physics.

Alemtuzumab and CHOP Chemotherapy for the Treatment of Aggressive Histology Peripheral T Cell Lymphomas: A Multi-Center Phase I Study.

G. Pond, K. Pritchard, V. Kukreti, 2016, Clinical lymphoma, myeloma & leukemia.

Correlation of changes between 2-year disease-free survival and 5-year overall survival in adjuvant breast cancer trials from 1966 to 2006.

G. Pond, L. Siu, P. Tang, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a Princess Margaret Hospital phase II consortium study.

E. Lamont, G. Pond, E. Vokes, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Claudin-Low Breast Cancer; Clinical & Pathological Characteristics

G. Pond, T. Whelan, M. Levine, 2017, PloS one.

UCN-01 in combination with topotecan in patients with advanced recurrent ovarian cancer: a study of the Princess Margaret Hospital Phase II consortium.

G. Pond, A. Oza, M. Carey, 2007, Gynecologic oncology.

High triple‐negative breast cancer prevalence and aggressive prognostic factors in Barbadian women with breast cancer

G. Pond, D. Skeete, Shawn M Hercules, 2020, Cancer.

Defining a 0.5-mb region of genomic gain on chromosome 6p22 in bladder cancer by quantitative-multiplex polymerase chain reaction.

A. Evans, G. Pond, B. Gallie, 2004, The American journal of pathology.

Statin use and survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide after docetaxel failure: the international retrospective observational STABEN study

G. Pond, G. Sonpavde, M. Milowsky, 2018, Oncotarget.

Weekly cyclophosphamide and alternate-day prednisone: an effective, convenient, and well-tolerated oral treatment for relapsed multiple myeloma after autologous stem cell transplantation.

G. Pond, S. Trudel, D. Reece, 2005, Mayo Clinic proceedings.

A prospective comparison of MRI‐US fused targeted biopsy versus systematic ultrasound‐guided biopsy for detecting clinically significant prostate cancer in patients on active surveillance

G. Pond, M. Haider, L. Klotz, 2015, Journal of magnetic resonance imaging : JMRI.

Influence of concurrent medications on outcomes of men with prostate cancer included in the TAX 327 study.

I. Tannock, G. Pond, R. de Wit, 2013, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

Concurrent gemcitabine and radiotherapy with and without neoadjuvant gemcitabine for locally advanced unresectable or resected pancreatic cancer: a phase I-II study.

G. Pond, A. Oza, D. Hedley, 2007, International journal of radiation oncology, biology, physics.

Metformin in Combination With Chemoradiotherapy in Locally Advanced Non-Small Cell Lung Cancer: The OCOG-ALMERA Randomized Clinical Trial.

G. Pond, P. Ellis, W. Roa, 2021, JAMA oncology.

Metformin inhibits growth and enhances radiation response of non-small cell lung cancer (NSCLC) through ATM and AMPK

G. Pond, G. Singh, T. Tsakiridis, 2013, British Journal of Cancer.

Long-term follow-up of secondary malignancies in adults after allogeneic bone marrow transplantation

G. Pond, J. Lipton, H. Messner, 2005, Bone Marrow Transplantation.

Immunohistochemical analysis of changes in signaling pathway activation downstream of growth factor receptors in pancreatic duct cell carcinogenesis

Joerg Schwock, Ming-Sound Tsao, David W Hedley, 2008, BMC Cancer.

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study.

I. Tannock, G. Pond, R. de Wit, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Angiotensin Blockade Modulates the Activity of PD1/L1 Inhibitors in Metastatic Urothelial Carcinoma.

G. Pond, G. Sonpavde, R. Jain, 2021, Clinical genitourinary cancer.

Neurocognitive function (NCF) in patients (pts) treated with chemo/bio-radiotherapy (C/B-RT) for head and neck cancers (HNC).

G. Pond, J. Waldron, A. Hope, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Tyrosine kinase inhibitors in chronic myeloid leukaemia and emergent cardiovascular disease

G. Pond, S. Karampatos, S. Rangarajan, 2021, Heart.

CLINICAL INVESTIGATION Brain ROLE OF FRACTIONATED EXTERNAL BEAM RADIOTHERAPY IN HEMANGIOBLASTOMA OF THE CENTRAL NERVOUS SYSTEM

G. Pond, C. Ménard, A. Nichol, 2022 .

Timing of Androgen Deprivation Therapy for Prostate Cancer Patients after Radiation: Planned Combined Analysis of Two Randomized Phase 3 Trials

Ryan L. Smith, M. Stockler, G. Pond, 2018, International Journal of Radiation Oncology*Biology*Physics.

Esthesioneuroblastoma: The Princess Margaret Hospital experience

R. Gilbert, G. Pond, B. O'Sullivan, 2008, Head & neck.

Prognostic factors for life expectancy in nonagenarians with nonmelanoma skin cancer: implications for selecting surgical candidates.

G. Pond, C. Otley, Alix J Charles, 2002, Journal of the American Academy of Dermatology.

Treatment-induced cell cycle kinetics dictate tumor response to chemotherapy

G. Pond, J. Hassell, J. Draper, 2015, Oncotarget.

Assumptions of expected benefits in randomized phase III trials evaluating systemic treatments for cancer.

G. Pond, E. Chen, H. Gan, 2012, Journal of the National Cancer Institute.

Timing of androgen deprivation therapy for prostate cancer patients after radiation: Planned combined analysis of two randomized phase 3 trials.

M. Stockler, G. Pond, H. Woo, 2018 .

Non-risk-adapted surveillance in clinical stage I nonseminomatous germ cell tumors: the Princess Margaret Hospital's experience.

G. Pond, P. Warde, M. Gospodarowicz, 2011, European urology.

Pretreatment neurocognitive function and self‐reported symptoms in patients with newly diagnosed head and neck cancer compared with noncancer cohort

Kelvin K. W. Chan, G. Pond, A. Hope, 2018, Head & neck.

Tumor factors predictive of response to hypofractionated radiotherapy in a randomized trial following breast conserving therapy.

G. Pond, T. Whelan, A. Fyles, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

A comparison of a new multinomial stopping rule with stopping rules of fleming and gehan in single arm phase II cancer clinical trials

G. Pond, D. Tu, J. Goffin, 2011, BMC medical research methodology.

Penile brachytherapy: results for 49 patients.

G. Pond, J. Crook, J. Jezioranski, 2005, International journal of radiation oncology, biology, physics.

Trends in incidence and mortality in rheumatoid arthritis in Rochester, Minnesota, over a forty-year period.

S. Gabriel, G. Pond, W. O'Fallon, 2002, Arthritis and rheumatism.

Association between the Lynch syndrome gene MSH2 and breast cancer susceptibility in a Canadian familial cancer registry

G. Pond, S. Gallinger, M. Aronson, 2017, Journal of Medical Genetics.

Improved 5-Factor Prognostic Classification of Patients Receiving Salvage Systemic Therapy for Advanced Urothelial Carcinoma.

G. Pond, T. Choueiri, G. Sonpavde, 2016, The Journal of urology.

Phase I Targeted Combination Trial of Sorafenib and Erlotinib in Patients with Advanced Solid Tumors

G. Pond, J. Dancey, L. Siu, 2007, Clinical Cancer Research.

Phase I Targeted CombinationTrial of Sorafenib and Erlotinib in Patients with Advanced SolidTumors

G. Pond, J. Dancey, L. Siu, 2007 .

Prospective comparison of rectal dose reduction during intracavitary brachytherapy for cervical cancer using three rectal retraction techniques.

G. Pond, T. Farrell, R. Sur, 2016, Brachytherapy.

Thyroid hormone receptor a in breast cancer: prognostic and therapeutic implications Katarzyna J. JerzakJessica CockburnGregory R. PondKathleen I. Pritchard • Steven A. NarodSukhbinder K. Dhesy-ThindAnita Bane

G. Pond, S. Narod, S. Dhesy-Thind, 2015 .

Thyroid hormone receptor α in breast cancer: prognostic and therapeutic implications

G. Pond, S. Narod, K. Pritchard, 2014, Breast Cancer Research and Treatment.

Do high symptom scores trigger clinical actions? An audit after implementing electronic symptom screening.

Jonathan Sussman, G. Pond, D. Bainbridge, 2012, Journal of oncology practice.

Five-Factor Prognostic Model for Survival of Post-Platinum Patients with Metastatic Urothelial Carcinoma Receiving PD-L1 Inhibitors.

G. Pond, T. Powles, T. Choueiri, 2020, The Journal of urology.

Complete response as an intermediate end point in patients receiving salvage systemic therapy for urothelial carcinoma.

G. Pond, P. Albers, T. Choueiri, 2015, Clinical genitourinary cancer.

The Influence of Mentorship on Research Productivity in Oncology

G. Pond, R. Riechelmann, L. Siu, 2007, American journal of clinical oncology.

Assessing the necessity of including a crossover period with dual reporting when changing total prostate-specific antigen methods.

G. Pond, S. Hotte, P. Kavsak, 2014, Clinical biochemistry.

Comparative survival analysis of multiparametric tests—when molecular tests disagree—A TEAM Pathology study

P. Boutros, G. Pond, D. Rea, 2021, NPJ breast cancer.

Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA

G. Pond, G. Naik, N. Agarwal, 2018, Cancer.

Assessing perfusion changes during whole brain irradiation for patients with cerebral metastases

G. Pond, T. Purdie, I. Yeung, 2005, Journal of Neuro-Oncology.

A phase II multi-institutional study assessing simultaneous in-field boost helical tomotherapy for 1-3 brain metastases

G. Pond, F. Lagerwaard, G. Bauman, 2012, Radiation oncology.

LUMINA: A prospective trial omitting radiotherapy (RT) following breast conserving surgery (BCS) in T1N0 luminal A breast cancer (BC).

T. Nielsen, G. Pond, T. Whelan, 2022, Journal of Clinical Oncology.

A phase II trial of dovitinib in previously-treated advanced pleural mesothelioma: The Ontario Clinical Oncology Group.

G. Pond, M. Levine, C. Addison, 2017, Lung cancer.

Identification of small molecules that sensitize resistant tumor cells to tumor necrosis factor-family death receptors.

G. Pond, John Calvin Reed, M. Konopleva, 2006, Cancer research.

A phase III randomized trial of the timing of meloxicam with iodine-125 prostate brachytherapy.

G. Pond, J. Crook, J. Borg, 2010, International journal of radiation oncology, biology, physics.

Single-agent Taxane Versus Taxane-containing Combination Chemotherapy as Salvage Therapy for Advanced Urothelial Carcinoma.

H. Kume, G. Pond, P. Albers, 2016, European urology.

Targeting metabolism and AMP-activated kinase with metformin to sensitize non-small cell lung cancer (NSCLC) to cytotoxic therapy: translational biology and rationale for current clinical trials

G. Pond, Jim A. Wright, T. Tsakiridis, 2017, Oncotarget.

A Novel Neoadjuvant Therapy for Operable Locally Invasive Non-Small-Cell Lung Cancer. Phase I Study of Neoadjuvant Stereotactic Body Radiotherapy. LINNEARRE I (NCT02433574).

G. Pond, M. Wierzbicki, T. Tsakiridis, 2017, Clinical lung cancer.

A phase I study of concurrent pemetrexed (P)/cisplatin (C)/radiation (RT) for unresectable stage IIIA/B non-small cell lung cancer (NSCLC)

G. Pond, A. Bezjak, F. Shepherd, 2008 .

A Comparison of Radiation Techniques in Patients Treated With Concurrent Chemoradiation for Stage III Non-Small Cell Lung Cancer.

G. Pond, P. Ellis, A. Swaminath, 2019, International journal of radiation oncology, biology, physics.

Posttreatment prognostic nomogram for patients with metastatic urothelial cancer completing first-line cisplatin-based chemotherapy.

G. Pond, G. Sonpavde, W. Oh, 2014, Urologic oncology.

Post-treatment prognostic model for patients (pts) with metastatic urothelial cancer (UC) treated with first-line chemotherapy.

G. Pond, G. Sonpavde, W. Oh, 2013, Journal of Clinical Oncology.

Influence of concurrent medications on outcomes of men with prostate cancer included in the TAX327 study.

I. Tannock, G. Pond, M. Eisenberger, 2010 .

The use and toxicity of steroids in the management of patients with brain metastases

G. Pond, A. Bezjak, R. Wong, 2008, Supportive Care in Cancer.

Prognostic factors in brain metastases: can we determine patients who do not benefit from whole-brain radiotherapy?

G. Pond, A. Bezjak, M. Lock, 2004, Clinical oncology (Royal College of Radiologists (Great Britain)).

Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy

Kimberly S. Chiew, I. Tannock, G. Pond, 2005, British Journal of Cancer.

Nomogram to assess benefit of new over historical agents as salvage therapy for metastatic urothelial carcinoma (mUC) in non-randomized trials: Effect of atezolizumab on 12-month survival.

G. Pond, T. Choueiri, G. Sonpavde, 2017 .

EPCT-11. RURALITY INDEX SCORE AND PEDIATRIC NEURO-ONCOLOGICAL OUTCOME IN ONTARIO

G. Pond, F. Farrokhyar, M. Kameda-Smith, 2021, Journal of neurosurgery. Pediatrics.

A phase II study of cediranib, an oral VEGF inhibitor, in previously untreated patients with metastatic or recurrent malignant melanoma

G. Pond, A. Oza, T. Gajewski, 2016, Investigational New Drugs.

Consistency in the analysis and reporting of primary end points in oncology randomized controlled trials from registration to publication: a systematic review.

G. Pond, E. Chen, H. Gan, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long-term survival after blood and marrow transplantation: comparison with an age- and gender-matched normative population.

G. Pond, J. Lipton, H. Messner, 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

A multi-centre study comparing granulocyte-colony stimulating factors to antibiotics for primary prophylaxis of docetaxel-cyclophosphamide induced febrile neutropenia

G. Pond, J. Mackey, B. Hutton, 2021, Breast.

Trajectory of Symptoms in Patients Undergoing Autologous Stem Cell Transplant for Multiple Myeloma: A Population-Based Cohort Study of Patient-Reported Outcomes.

G. Pond, H. Seow, T. Wildes, 2021, Clinical lymphoma, myeloma & leukemia.

Factors influencing the use of single vs multiple fractions of palliative radiotherapy for bone metastases: a 5-year review.

G. Pond, A. Bezjak, M. Mclean, 2005, Clinical oncology (Royal College of Radiologists (Great Britain)).

Time interval between endometrial biopsy and surgical staging for type I endometrial cancer: association between tumor characteristics and survival outcome.

G. Pond, L. Elit, H. Seow, 2015, Obstetrics and gynecology.

A Phase 2 study of perifosine in advanced or metastatic breast cancer

G. Pond, J. Dancey, D. Hedley, 2008, Breast Cancer Research and Treatment.

The impact of chemotherapy-induced cognitive impairment on the psychosocial adjustment of patients with nonmetastatic colorectal cancer.

G. Pond, J. Galica, D. Rajacich, 2012, Clinical journal of oncology nursing.

Randomised, phase II, placebo-controlled, trial of fulvestrant plus vandetanib in postmenopausal women with bone only or bone predominant, hormone-receptor-positive metastatic breast cancer (MBC): the OCOG ZAMBONEY study

G. Pond, A. Robidoux, S. Chia, 2014, Breast Cancer Research and Treatment.

A phase II, multicentre trial evaluating the efficacy of de-escalated bisphosphonate therapy in metastatic breast cancer patients at low-risk of skeletal-related events

G. Pond, G. Dranitsaris, M. Clemons, 2014, Breast Cancer Research and Treatment.

Neuroendocrine Tumors of the Gastrointestinal Tract: A Decade of Experience at the Princess Margaret Hospital

G. Pond, J. Brierley, M. Moore, 2008, American journal of clinical oncology.

Neuroendocrine tumors (NET) of the gastrointestinal tract: A decade of experience at the Princess Margaret Hospital.

G. Pond, S. Gallinger, L. Siu, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Weekly vinblastine in chemotherapy-naive children with unresectable or progressive low grade glioma: A Canadian cooperative study.

G. Pond, C. Hawkins, K. Poskitt, 2013 .

The Contents and Readability of Informed Consent Forms for Oncology Clinical Trials

G. Pond, R. Heslegrave, L. Siu, 2010, American journal of clinical oncology.

G. Pond, H. Seow, C. Eskicioglu, 2019, Inflammatory bowel diseases.

Factors associated with publication of randomized phase iii cancer trials in journals with a high impact factor.

G. Pond, S. Welch, P. Tang, 2014, Current oncology.

Quality of reporting of modern randomized controlled trials in medical oncology: a systematic review.

G. Pond, E. Chen, H. Gan, 2012, Journal of the National Cancer Institute.

Improving the Quality of Abstract Reporting for Phase I Cancer Trials

G. Pond, L. Siu, A. Murgo, 2008, Clinical Cancer Research.

Early initiation of palliative care is associated with reduced late-life acute-hospital use: A population-based retrospective cohort study

G. Pond, R. Perez, P. Tanuseputro, 2018, Palliative medicine.

Utility of the Edmonton Frail Scale in identifying frail elderly patients during treatment of colorectal cancer.

G. Pond, A. Papaioannou, K. Zbuk, 2017, Journal of gastrointestinal oncology.

Chronic obstructive pulmonary disease prevalence and prediction in a high-risk lung cancer screening population

S. Lam, G. Pond, A. Tremblay, 2020, BMC Pulmonary Medicine.

Feasibility and Effectiveness of Self-Management Education and Coaching on Patient Activation for Managing Cancer Treatment Toxicities.

G. Pond, V. Kukreti, D. Bryant-Lukosius, 2023, Journal of the National Comprehensive Cancer Network : JNCCN.

Effects on bone resorption markers of continuing pamidronate or switching to zoledronic acid in patients with high risk bone metastases from breast cancer

G. Pond, M. Clemons, C. Addison, 2017, Journal of bone oncology.

Pharmacist medication assessments in a surgical preadmission clinic.

J. Bajcar, Olavo A Fernandes, G. Pond, 2007, Archives of internal medicine.

Phase II study of bortezomib in advanced or metastatic urothelial cancer. A trial of the Princess Margaret Hospital [PMH] Phase II Consortium

G. Pond, E. Vokes, D. Hedley, 2005 .

Improving observer variability in target delineation for gastro-oesophageal cancer--the role of (18F)fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography.

K. Brock, G. Pond, M. Haider, 2008, Clinical oncology (Royal College of Radiologists (Great Britain)).

Geriatric assessment and quality of life changes in older adults with newly diagnosed multiple myeloma undergoing treatment.

G. Pond, S. Tuchman, M. Fiala, 2020, Journal of geriatric oncology.

A Phase II Trial of Erlotinib and Concurrent Palliative Thoracic Radiation for Patients With Non-Small-Cell Lung Cancer.

G. Pond, Y. Ung, T. Tsakiridis, 2016, Clinical lung cancer.

Selecting Patients for Oncotype DX Testing Using Standard Clinicopathologic Information.

G. Pond, Z. Kos, M. Clemons, 2020, Clinical breast cancer.

Do beta-blockers alter dyspnea and fatigue in advanced lung cancer? A retrospective analysis

G. Pond, P. Ellis, J. Goffin, 2012, Palliative medicine.

A target based approach identifies genomic predictors of breast cancer patient response to chemotherapy

Gregory Pond, G. Pond, J. Hassell, 2012, BMC Medical Genomics.

Prognostic indices of inflammatory markers, cognitive function and fatigue for survival in patients with localised colorectal cancer

I. Tannock, G. Pond, S. Clarke, 2018, ESMO Open.

Cognitive function and fatigue after diagnosis of colorectal cancer.

I. Tannock, G. Pond, S. Clarke, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Prognostic risk stratification derived from individual patient level data for men with advanced penile squamous cell carcinoma receiving first-line systemic therapy.

G. Pond, G. Sonpavde, M. Galsky, 2014, Urologic oncology.

Validation of the Association of RECIST Changes With Survival in Men With Metastatic Castration‐Resistant Prostate Cancer Treated on SWOG Study S0421

G. Pond, I. Thompson, C. Tangen, 2017, Clinical genitourinary cancer.

Association Between RECIST Changes and Survival in Patients with Metastatic Castration-resistant Prostate Cancer Receiving Docetaxel.

G. Pond, G. Sonpavde, A. Armstrong, 2016, European urology.

A feasibility study of an internal control methodology using hydrocortisone cream for the management of skin reactions in patients receiving radical radiation therapy for cancers of the head and neck

G. Pond, J. Waldron, A. Cashell, 2006, Journal of Radiotherapy in Practice.

A Randomized Controlled Trial Comparing Alloderm-RTU with DermACELL in Immediate Subpectoral Implant-Based Breast Reconstruction

G. Pond, B. Hutton, M. Clemons, 2020, Current oncology.

Assessment of Referral and Chemotherapy Treatment Patterns for Elderly Patients With Non-small-Cell Lung Cancer.

G. Pond, P. Ellis, D. Dawe, 2016, Clinical lung cancer.

A comparison of patient knowledge of clinical trials and trialist priorities.

G. Pond, P. Ellis, J. Goffin, 2013, Current oncology.

Regularly scheduled physical examinations and the detection of breast cancer recurrences

G. Pond, M. Clemons, L. Vandermeer, 2023, Breast.

Fertility risk discussions in young patients diagnosed with colorectal cancer.

G. Pond, K. Zbuk, A. Kumar, 2012, Current oncology.

Prognostic impact of the neutrophil-to-lymphocyte ratio in men with metastatic castration-resistant prostate cancer.

Gregory R Pond, Arnoud J Templeton, Andrew J Armstrong, 2014, Clinical genitourinary cancer.

The nature and extent of urinary morbidity in relation to prostate brachytherapy urethral dosimetry.

G. Pond, I. Yeung, M. Mclean, 2007, Brachytherapy.

Evaluating the value of number of cycles of docetaxel and prednisone in men with metastatic castration-resistant prostate cancer.

W. Berry, I. Tannock, G. Pond, 2012, European urology.

The association between radiographic response and overall survival in men with metastatic castration‐resistant prostate cancer receiving chemotherapy

Gregory R Pond, Ian F Tannock, Andrew J Armstrong, 2011, Cancer.

Phase II study of pegylated liposomal doxorubicin HCl (Caelyx) in combination with cyclophosphamide and vincristine as second-line treatment of patients with small cell lung cancer.

G. Pond, J. Dancey, F. Shepherd, 2003, Lung cancer.

A phase I study of pegylated liposomal doxorubicin hydrochloride (Caelyx) in combination with cyclophosphamide and vincristine as second-line treatment of patients with small-cell lung cancer.

G. Pond, J. Dancey, F. Shepherd, 2003, Clinical lung cancer.

A nomogram including baseline prognostic factors to estimate the activity of second‐line therapy for advanced urothelial carcinoma

G. Pond, P. Albers, T. Choueiri, 2014, BJU international.

Results of a multicenter randomized trial to evaluate a survivorship care plan for breast cancer survivors.

G. Pond, A. Robidoux, K. Pritchard, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Genitourinary tumors, non-prostate

S. J. Park, I. Tannock, S. Groshen, 2012 .

Direct Medical Costs Attributable to Osteoporotic Fractures

S. Gabriel, G. Pond, A. Tosteson, 2002, Osteoporosis International.

Development of a Prediction Tool for Exclusive Locoregional Recurrence After Radical Cystectomy in Patients With Muscle‐Invasive Bladder Cancer

G. Pond, F. Montorsi, N. Agarwal, 2019, Clinical genitourinary cancer.

Bone Metastases as the Only Metastatic Site in Patients With Urothelial Carcinoma: Focus on a Special Patient Population

G. Pond, T. Powles, N. Agarwal, 2018, Clinical genitourinary cancer.

Analysis of treatment practices for elderly cancer patients in Ontario, Canada.

G. Pond, S. Straus, L. Siu, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II trial of cytoreductive stereotactic hypofractionated radiotherapy with combination ipilimumab/nivolumab for metastatic kidney cancer (CYTOSHRINK).

M. Surette, G. Pond, A. Kapoor, 2020, Journal of Clinical Oncology.

Early tumor shrinkage is independently associated with improved overall survival among patients with metastatic renal cell carcinoma: a validation study using the COMPARZ cohort

G. Pond, V. Grünwald, M. Dietrich, 2018, World Journal of Urology.

A survivorship care plan for breast cancer survivors: extended results of a randomized clinical trial

G. Pond, D. Coyle, M. Levine, 2015, Journal of Cancer Survivorship.

The Decision to Accept Treatment for Osteoporosis Following Hip Fracture: Exploring the Woman’s Perspective Using a Stage-of-Change Model

G. Pond, R. Trousdale, K. Mauck, 2002, Osteoporosis International.

Management and outcomes of patients with chronic obstructive lung disease and lung cancer in a public healthcare system

G. Pond, J. Goffin, Sophie Corriveau, 2021, PloS one.

Trial marketing in the Pan-Canadian Early Detection of Lung Cancer Study

S. Lam, G. Pond, A. Tremblay, 2020, Clinical trials.

Influence of an independent review committee on assessment of response rate and progression-free survival in phase III clinical trials.

G. Pond, P. Tang, E. Chen, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Risk Perception Among a Lung Cancer Screening Population.

S. Lam, G. Pond, A. Tremblay, 2021, Chest.

A phase II trial of temsirolimus in metastatic neuroendocrine carcinomas (NECs)

G. Pond, J. Dancey, L. Siu, 2005 .

The effect of obesity on rectal dosimetry after permanent prostate brachytherapy.

G. Pond, J. Crook, E. Saibishkumar, 2009, Brachytherapy.

A phase II study of PS-341 (Bortezomib) in advanced or metastatic urothelial cancer. A trial of the Princess Margaret Hospital and University of Chicago phase II consortia

G. Pond, M. Moore, J. Wright, 2006, Investigational New Drugs.

The impact of an educational DVD on cancer patients considering participation in a phase I clinical trial

G. Pond, L. Siu, M. Maclean, 2007, Supportive Care in Cancer.

Factors associated with not receiving homecare, end-of-life homecare, or early homecare referral among cancer decedents: A population-based cohort study.

G. Pond, L. Barbera, D. Bainbridge, 2015, Health policy.

The utility of transition zone index in predicting acute urinary morbidity after 125I prostate brachytherapy.

G. Pond, M. Mclean, J. Crook, 2002, Brachytherapy.

Validation of a modified VOICES survey to measure end-of-life care quality: the CaregiverVoice survey

G. Pond, J. Cairney, M. Brouwers, 2017, BMC Palliative Care.

Comparison of absolute benefits of anticancer therapies determined by snapshot and area methods.

I. Tannock, G. Pond, A. Ocaña, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Oncologic Outcomes of Surgically Treated Cervical Cancer with No Residual Disease on Hysterectomy Specimen: A 4C (Canadian Cervical Cancer Collaborative) Working Group Study

G. Pond, J. Kwon, L. Elit, 2023, Current oncology.

Web-Based Asynchronous Tool to Facilitate Communication Between Primary Care Providers and Cancer Specialists: Pragmatic Randomized Controlled Trial

G. Pond, M. O’Brien, C. Liddy, 2023, Journal of medical Internet research.

Reply to M. Jefford et al and C.T. Stricker et al

G. Pond, D. Coyle, E. Grunfeld, 2012 .

Improved prognostic classification of patients receiving salvage systemic therapy for advanced urothelial carcinoma.

G. Pond, P. Albers, T. Choueiri, 2015 .

Phase II study of ispinesib in recurrent or metastatic squamous cell carcinoma of the head and neck

G. Pond, L. Siu, S. Chia, 2008, Investigational New Drugs.

Influence of statistician involvement on reporting of randomized clinical trials in medical oncology

G. Pond, E. Chen, H. Gan, 2013, Anti-cancer drugs.

The LISA randomized trial of a weight loss intervention in postmenopausal breast cancer

G. Pond, J. Gralow, A. Robidoux, 2020, npj Breast Cancer.

Association of pain and quality of life (QOL) response with PSA response and survival of patients (pts) with metastatic hormone refractory prostate cancer (mHRPC) treated with docetaxel or mitoxantrone in the TAX-327 study.

I. Tannock, G. Pond, R. de Wit, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical outcomes and prognostic biomarkers among pregnant, post-partum and nulliparous women with breast cancer: a prospective cohort study

G. Pond, E. Warner, S. Nofech-Mozes, 2021, Breast Cancer Research and Treatment.

Computerized tomographic simulation compared with clinical mark-up in palliative radiotherapy: a prospective study.

G. Pond, A. Bezjak, M. Mclean, 2006, International Journal of Radiation Oncology, Biology, Physics.

External validation of the FIRST trial’s simplified frailty score in a population-based cohort

G. Pond, H. Seow, T. Wildes, 2021, Leukemia.

G. Pond, N. Hanna, L. Einhorn, 2017, Clinical genitourinary cancer.

Outcomes in Elderly Patients with Glioblastoma Multiforme Treated with Short-Course Radiation Alone Compared to Short-Course Radiation and Concurrent and Adjuvant Temozolomide Based on Performance Status and Extent of Resection

G. Pond, J. Greenspoon, Taskia Mir, 2021, Current oncology.

Cost-effectiveness of a survivorship care plan for breast cancer survivors.

G. Pond, D. Coyle, K. Coyle, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Are family physician visits and continuity of care associated with acute care use at end-of-life? A population-based cohort study of homecare cancer patients

G. Pond, K. Brazil, H. Seow, 2014, Palliative medicine.

Relationship of the International Prostate Symptom score with urinary flow studies, and catheterization rates following 125I prostate brachytherapy.

G. Pond, M. Mclean, J. Crook, 2006, Brachytherapy.

Preoperative radiation with concurrent chemotherapy for resectable rectal cancer: effect of dose escalation on pathologic complete response, local recurrence-free survival, disease-free survival, and overall survival.

G. Pond, A. Oza, John J. Kim, 2006, International Journal of Radiation Oncology, Biology, Physics.

A Phase 3, Multicenter, Randomized Trial to Evaluate the Symptomatic and Quality of Life Improvements in Lung Cancer Patients Receiving External Beam Radiation With or Without High Dose Rate Intraluminal Brachytherapy

G. Pond, T. Whelan, A. Bezjak, 2017 .

Effect of Positron Emission Tomography Imaging in Women With Locally Advanced Cervical Cancer

Gregory R. Pond, David D’Souza, Timothy J. Whelan, 2018, JAMA network open.

Exclusion of Patients With Brain Metastases in Published Phase III Clinical Trials for Advanced Breast Cancer.

G. Pond, K. Jerzak, Stephanie Chan, 2022, Clinical breast cancer.

Central Nervous System-Specific Outcomes of Phase 3 Randomized Clinical Trials in Patients With Advanced Breast Cancer, Lung Cancer, and Melanoma.

G. Pond, P. Brastianos, A. Sahgal, 2021, JAMA oncology.

The unclear zone in phase II clinical trials.

G. Pond, S. Hotte, S. Allegro, 2010, European journal of cancer.

Multidisciplinary health care professionals' perceptions of the use and utility of a symptom assessment system for oncology patients.

Jonathan Sussman, G. Pond, D. Bainbridge, 2011, Journal of oncology practice.

The effect of age on referral to an oncologist and receipt of chemotherapy among small cell lung cancer patients in Ontario, Canada.

G. Pond, P. Ellis, D. Dawe, 2014, Journal of geriatric oncology.

Chemo-Immunotherapy in First Line Extensive Stage Small Cell Lung Cancer (ES-SCLC): A Systematic Review and Meta-Analysis

G. Pond, P. Ellis, A. Sathiyapalan, 2022, Current oncology.

Circulating Tumor DNA Alterations in Advanced Urothelial Carcinoma and Association with Clinical Outcomes: A Pilot Study.

G. Pond, G. Naik, N. Agarwal, 2020, European urology oncology.

Evaluation of Adverse Events Experienced by Older Patients Participating in Studies of Molecularly Targeted Agents Alone or in Combination

G. Pond, A. Oza, H. Hirte, 2006, Clinical Cancer Research.

Can the referring surgeon enhance accrual of breast cancer patients to medical and radiation oncology trials? The ENHANCE study.

G. Pond, M. Clemons, S. Gertler, 2016, Current oncology.

Tolerability of the Intergroup 0099 (INT 0099) regimen in locally advanced nasopharyngeal cancer with a focus on patients' nutritional status.

I. Tannock, G. Pond, B. O'Sullivan, 2004, International journal of radiation oncology, biology, physics.

Design and analysis of sequential clinical trials using a Markov chain transition rate model with conditional power.

Gregory Russell Pond, G. Pond, 2008 .

MP-21.03: Penile brachytherapy: results for 60 patients

G. Pond, J. Crook, B. Esche, 2007 .

Penile brachytherapy: Results for 60 patients

G. Pond, J. Crook, B. Esche, 2007 .

Circulating tumor (ct)-DNA alterations in metastatic castration-resistant prostate cancer (mCRPC): Association with outcomes and evolution with therapy.

G. Pond, G. Naik, N. Agarwal, 2017 .

Integration of Bone and Computed Tomography Scans to Assess Bone Metastasis in Metastatic Castration‐Resistant Prostate Cancer

G. Pond, N. Agarwal, G. Sonpavde, 2017, Clinical genitourinary cancer.

Radiation dose to the internal pudendal arteries from permanent-seed prostate brachytherapy as determined by time-of-flight MR angiography.

G. Pond, I. Yeung, J. Crook, 2006, International journal of radiation oncology, biology, physics.

Treating fibromyalgia with a brief interdisciplinary program: initial outcomes and predictors of response.

G. Pond, L. Krahn, C. Sletten, 2001, Mayo Clinic proceedings.

A Phase I/II Study of GTI-2040 Plus Docetaxel as Second-Line Treatment in Advanced Non-small Cell Lung Cancer: A Study of the PMH Phase II Consortium

G. Pond, Y. Yen, F. Shepherd, 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Statistical issues in the use of dynamic allocation methods for balancing baseline covariates

G. Pond, Gregory R. Pond, 2011, British Journal of Cancer.

Reply to D.J. Stewart

G. Pond, M. Moore, L. Siu, 2010 .

Statistical and analytical approaches for assessing biomarkers: new approaches, new technologies, with the same-old rigor for evaluation.

Peter A Kavsak, Matthew P A Henderson, Gregory R Pond, 2012, Clinical biochemistry.

Independent predictors of prolonged operative time during robotic-assisted radical prostatectomy

G. Pond, S. Pautler, P. Violette, 2015, Journal of Robotic Surgery.

357 Impact of Survivorship Care Plans (SCP) On Adherence to Guidelines, Health Service Measures, and Patient-reported Outcomes (PRO): Extended Results of a Multicenter Randomized Clinical Trial (RCT) with Breast Cancer Survivors

G. Pond, D. Coyle, M. Levine, 2012 .

Receptors Tumor Cells to Tumor Necrosis Factor-Family Death Identification of Small Molecules that Sensitize Resistant

G. Pond, John Calvin Reed, M. Konopleva, 2006 .

Types of Variables and Distributions

G. Pond, S. Caetano, 2018 .

Robot-assisted Versus Open Radical Cystectomy in Patients Receiving Perioperative Chemotherapy for Muscle-invasive Bladder Cancer: The Oncologist's Perspective from a Multicentre Study.

G. Pond, T. Powles, N. Agarwal, 2017, European Urology Focus.

Tolerability and efficacy of chemotherapy in older men with metastatic castrate-resistant prostate cancer (mCRPC) in the TAX 327 trial.

I. Tannock, G. Pond, R. de Wit, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Isamed Journals

G. Pond, L. Elit, H. Hirte, 2017 .

Essential Statistical Tests

G. Pond, S. Caetano, 2019, Principles and Practice of Clinical Trials.

Association of immune-related adverse events (irAEs) with clinical benefit in patients with metastatic urothelial carcinoma (mUC) treated with immune-checkpoint inhibitors (ICIs).

G. Pond, T. Choueiri, G. Sonpavde, 2019, Journal of Clinical Oncology.

G. Pond, A. Scott, S. Punwani, 2018, The Journal of Nuclear Medicine.

The Impact of Adding Taxanes to Gemcitabine and Platinum Chemotherapy for the First-Line Therapy of Advanced or Metastatic Urothelial Cancer: A Systematic Review and Meta-analysis.

G. Pond, G. Naik, G. Sonpavde, 2016, European urology.

Impact of pure versus mixed metastatic urothelial carcinoma (mUC) histology on response with immune checkpoint inhibitors (ICIs).

G. Pond, G. Sonpavde, A. Acosta, 2019, Journal of Clinical Oncology.

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study.

I. Tannock, G. Pond, R. de Wit, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Serum alkaline phosphatase changes predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy.

I. Tannock, G. Pond, G. Sonpavde, 2012, Urologic oncology.

The prognostic importance of metastatic site in men with metastatic castration-resistant prostate cancer.

I. Tannock, G. Pond, G. Sonpavde, 2014, European urology.

Translating clinical trials to clinical practice: outcomes of men with metastatic castration resistant prostate cancer treated with docetaxel and prednisone in and out of clinical trials.

I. Tannock, G. Pond, M. Moore, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Prognostic Impact of C-Reactive Protein in Metastatic Prostate Cancer: A Systematic Review and Meta-Analysis

G. Pond, G. Naik, G. Sonpavde, 2014, Oncology Research and Treatment.

Posttreatment Complications of Early‐Stage Prostate Cancer Patients: Brachytherapy Versus Three‐Dimensional Conformal Radiation Therapy

Caitlin Gillan, Charles Catton, Gregory Pond, 2005, Cancer journal.

Identification of small molecules that sensitize resistant tumor cells to tumor necrosis factor-family death receptors.

G. Pond, John Calvin Reed, M. Konopleva, 2006, Cancer research.

Metformin for chemo-radio-sensitization of NSCLC.

G. Pond, T. Tsakiridis, H. Skinner, 2016, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Intraoperative Sonographically Assisted Radioactive Iodine 125 Plaque Brachytherapy for Choroidal Melanoma

G. Pond, G. Shenouda, T. AlMahmoud, 2013, Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine.

Outcome Analysis of Visual Acuity and Side Effect after Ruthenium-106 Plaque Brachytherapy for Medium-sized Choroidal Melanoma

G. Pond, T. AlMahmoud, J. Deschênes, 2018, Middle East African journal of ophthalmology.

A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas

G. Pond, A. Oza, D. Birle, 2006, British Journal of Cancer.

Trainee Evaluations of Preparedness for Clinical Trials in Medical Oncology—A National Questionnaire

G. Pond, R. Juergens, G. Kazemi, 2023, Current Oncology.

Rurality index score and pediatric neuro-oncological outcome in Ontario.

G. Pond, M. Kameda-Smith, H. Seow, 2023, Journal of neurosurgery. Pediatrics.

Examining the safety and efficacy of a chemotherapy dosing method in Allogeneic Stem Cell Transplant patients of extreme body size

G. Pond, J. Lipton, H. Messner, 2009, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

Cardiac and inflammation biomarker profile after initiation of adjuvant trastuzumab therapy.

G. Pond, P. Ellis, P. Kavsak, 2013, Clinical Chemistry.

Non-risk-adapted surveillance in clinical stage I nonseminomatous germ cell tumors: the Princess Margaret Hospital's experience.

G. Pond, P. Warde, M. Gospodarowicz, 2011, European urology.

The unclear zone in phase II clinical trials.

G. Pond, S. Hotte, S. Allegro, 2010, European journal of cancer.

A randomized clinical trial comparing physician-directed or fixed-dose steroid replacement strategies for incomplete dexamethasone dosing prior to docetaxel chemotherapy

G. Pond, B. Hutton, M. Clemons, 2020, Supportive Care in Cancer.

The Contents and Readability of Informed Consent Forms for Oncology Clinical Trials

G. Pond, R. Heslegrave, L. Siu, 2010, American journal of clinical oncology.

A Multi-Centre Randomized Study Comparing Two Standard of Care Chemotherapy Regimens for Lower-Risk HER2-Positive Breast Cancer

G. Pond, D. Cella, M. Clemons, 2023, Current oncology.

Cardiac Morbidity Following Chemoradiation in Stage III Non-small Cell Lung Cancer Patients: A Population-Based Cohort Study.

G. Pond, P. Ellis, A. Swaminath, 2022, Clinical oncology (Royal College of Radiologists (Great Britain)).

The impact of staging FDG-PET/CT on treatment for stage III NSCLC - an analysis of population-based data from Ontario, Canada

G. Pond, T. Tsakiridis, A. Swaminath, 2023, Frontiers in oncology.